{"id":450,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"modified":"2026-08-28T07:42:46","modified_gmt":"2026-08-28T07:42:46","slug":"retatrutide-development-status-2026-evidence-map","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/de\/retatrutide-development-status-2026-evidence-map\/","title":{"rendered":"Retatrutide-Entwicklungsstatus in 2026: Eine Evidenzkarte f\u00fcr Forscher"},"content":{"rendered":"

Verbindungen in der Entwicklungsphase stellen ein wiederkehrendes SEO-Genauigkeitsproblem dar: Testank\u00fcndigungen, Registrierungsstatus, Konferenzberichte, Zeitschriftenartikel und Genehmigungen werden h\u00e4ufig in einer Zeitleiste zusammengefasst. Diese Evidenzkarte h\u00e4lt diese Meilensteine \u200b\u200bf\u00fcr Retatrutid getrennt.<\/p>

Wichtige Erkenntnisse<\/h2>
  • Peer-reviewte Phase-2-Ergebnisse und ein abgeschlossener Phase-3-Registrierungseintrag sind unterschiedliche Beweisobjekte.<\/li>
  • ClinicalTrials.gov zeigt immer noch keine ver\u00f6ffentlichten Ergebnisse f\u00fcr TRIUMPH-1 an, w\u00e4hrend 2026-Sponsor-Topline-Offenlegungen jetzt vorliegen; Diese Beweisgegenst\u00e4nde werden nachstehend separat aufgef\u00fchrt.<\/li>
  • Der Regulierungsstatus sollte anhand der FDA-Datens\u00e4tze \u00fcberpr\u00fcft werden und nicht aus der Medienberichterstattung oder der Katalogverf\u00fcgbarkeit abgeleitet werden.<\/li><\/ul><\/div><\/div>
    \"Forscher
    Konzeptionelle Darstellung der Multirezeptorforschung; Es werden keine Versuchsergebnisse oder Produktpr\u00e4sentationen dargestellt.<\/figcaption><\/figure>

    Die Beweisleiter<\/h2>

    Ein Studienregister beantwortet Protokoll- und Statusfragen: Was war geplant, wer war teilnahmeberechtigt, welche Ergebnisse wurden festgelegt und ob die Rekrutierung oder Nachverfolgung abgeschlossen ist. Ein Zeitschriftenartikel beantwortet nach Datenanalyse und Peer-Review eine andere Reihe von Fragen. Ein FDA-Genehmigungsdatensatz f\u00fcgt eine unabh\u00e4ngige beh\u00f6rdliche Bestimmung f\u00fcr ein bestimmtes Produkt hinzu.<\/p>

    Ver\u00f6ffentlicht<\/strong>Phase-2-Fettleibigkeitsstudie mit peer-reviewten Ergebnissen<\/span><\/div>
    Registriert\/abgeschlossen<\/strong>TRIUMPH-1-Phase 3-Datensatz; Status- und Protokollinformationen<\/span><\/div>
    Sponsor berichtet<\/strong>2026-Topline-Phase 3-Ergebnisse; noch nicht vollst\u00e4ndige peer-reviewte Berichte<\/span><\/div>
    ClinicalTrials.gov<\/strong>TRIUMPH-1 zeigt immer noch \u201eKeine Ergebnisse ver\u00f6ffentlicht\u201c an<\/span><\/div>
    Nicht etabliert<\/strong>FDA-Zulassung f\u00fcr Retatrutid<\/span><\/div><\/div><\/div>

    So aktualisieren Sie diese Seite verantwortungsvoll<\/h2>

    Wenn sich eine Registrierung \u00e4ndert, notieren Sie das Aktualisierungsdatum und beschreiben Sie nur das ge\u00e4nderte Feld. Wenn Ergebnisse angezeigt werden, verkn\u00fcpfen Sie den Ergebnisdatensatz oder die peer-reviewte Ver\u00f6ffentlichung und unterscheiden Sie vorab festgelegte Endpunkte von explorativen Analysen. Wenn sich der Regulierungsstatus \u00e4ndert, ersetzen Sie die alte Statuserkl\u00e4rung und f\u00fcgen Sie sie nicht einfach hinzu.<\/p>

    Aktualisieren Sie das Artikeldatum nicht ohne wesentliche \u00c4nderungen der Beweise. Googles \u201ePeople First\u201c-Leitfaden warnt ausdr\u00fccklich davor, Daten zu \u00e4ndern, nur um den Inhalt aktuell erscheinen zu lassen.<\/p>

    Von 2026 gesponserte Phase 3-Oberlinie<\/h2>

    Lilly berichtete im Mai \u00fcber Topline-Ergebnisse f\u00fcr TRIUMPH-1. 21, 2026: In den 80-Wochen meldete der Sponsor eine durchschnittliche Gewichtsver\u00e4nderung von \u221228.3% f\u00fcr die 12-mg-Gruppe. Im Juli berichteten 23, 2026, Lilly mittlere \u00c4nderungen bis zu \u221220.8% in TRIUMPH-2 und \u221222.6% in TRIUMPH-3. Hierbei handelt es sich um Offenlegungen von Hauptsponsoren, nicht um Ergebnismodule von ClinicalTrials.gov oder vollst\u00e4ndige, von Experten \u00fcberpr\u00fcfte Berichte. F\u00fcr detaillierte Methoden, Analyseentscheidungen und vollst\u00e4ndige Tabellen zu unerw\u00fcnschten Ereignissen sind weiterhin vollst\u00e4ndige Aufzeichnungen erforderlich. ClinicalTrials.gov zeigte bei dieser \u00dcberpr\u00fcfung weiterhin \u201eKeine Ergebnisse ver\u00f6ffentlicht\u201c f\u00fcr TRIUMPH-1 an.<\/p>

    Auswirkungen auf Katalogrechercheseiten<\/h2>

    Eine Katalogseite kann den Entwicklungszeitplan als Orientierung f\u00fcr Forscher verwenden, muss jedoch die Trennung zwischen Literaturnachweisen und Losqualit\u00e4t wahren. Es sollte auf die Spezifikations- und Nachweismodule der Familie verweisen und darauf hinweisen, dass das Material nicht f\u00fcr den menschlichen oder veterin\u00e4rmedizinischen Gebrauch bestimmt ist.<\/p>","protected":false},"excerpt":{"rendered":"

    Eine 2026-Evidenzkarte, die die ver\u00f6ffentlichten 2-Daten der Retatrutid-Phase, die Aufzeichnungen der abgeschlossenen 3-Studien, die nicht ver\u00f6ffentlichten Ergebnisse und den regulatorischen Status trennt.<\/p>","protected":false},"author":1,"featured_media":620,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"359","pim_article_type":"Development-status evidence map","pim_evidence_level":"Trial registry, peer-reviewed phase 2 evidence and FDA status","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Retatrutide phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\",\"note\":\"Peer-reviewed outcomes.\"},{\"title\":\"TRIUMPH-1 ClinicalTrials.gov record\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\",\"note\":\"Protocol and current study-status record.\"},{\"title\":\"FDA current information on retatrutide status\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Authoritative regulatory boundary.\"},{\"title\":\"TRIUMPH-1 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\",\"note\":\"Lilly primary-sponsor news release, May 21, 2026; not a peer-reviewed full report.\"},{\"title\":\"TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-successful-two-additional\",\"note\":\"Lilly primary-sponsor news release, July 23, 2026; detailed results remain pending.\"},{\"title\":\"Google guidance on people-first content and substantive date changes\",\"url\":\"https:\/\/developers.google.com\/search\/docs\/fundamentals\/creating-helpful-content\",\"note\":\"Official Google Search Central guidance cited for the editorial-update statement.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-450","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\nRetatrutide Development Status in 2026: An Evidence Map for Researchers - NHD<\/title>\n<meta name=\"description\" content=\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/retatrutide-development-status-2026-evidence-map\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\" \/>\n<meta property=\"og:description\" content=\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/retatrutide-development-status-2026-evidence-map\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\",\"name\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"description\":\"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-development-status-2026-evidence-map-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-development-status-2026-evidence-map\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide Development Status in 2026: An Evidence Map for Researchers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/de\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Retatrutide-Entwicklungsstatus in 2026: Eine Evidenzkarte f\u00fcr Forscher \u2013 NHD","description":"Eine 2026-Evidenzkarte, die die ver\u00f6ffentlichten 2-Daten der Retatrutid-Phase, die Aufzeichnungen der abgeschlossenen 3-Studien, die nicht ver\u00f6ffentlichten Ergebnisse und den regulatorischen Status trennt.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/retatrutide-development-status-2026-evidence-map\/","og_locale":"de_DE","og_type":"article","og_title":"Retatrutide Development Status in 2026: An Evidence Map for Researchers","og_description":"A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.","og_url":"https:\/\/nhdbio.com\/de\/retatrutide-development-status-2026-evidence-map\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:42:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Verfasst von":"NHD Technical Team","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Retatrutide Development Status in 2026: An Evidence Map for Researchers","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/","url":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/","name":"Retatrutide-Entwicklungsstatus in 2026: Eine Evidenzkarte f\u00fcr Forscher \u2013 NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","description":"Eine 2026-Evidenzkarte, die die ver\u00f6ffentlichten 2-Daten der Retatrutid-Phase, die Aufzeichnungen der abgeschlossenen 3-Studien, die nicht ver\u00f6ffentlichten Ergebnisse und den regulatorischen Status trennt.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-development-status-2026-evidence-map-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/retatrutide-development-status-2026-evidence-map\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide Development Status in 2026: An Evidence Map for Researchers"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD Technisches Team","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"Das technische Team von NHD verwaltet Katalogdokumentationen und Beweiszusammenfassungen f\u00fcr Forschungszwecke. Rezensierte Artikel verweisen auf von Experten begutachtete Artikel, Studienregister und beh\u00f6rdliche Aufzeichnungen, behalten Nullergebnisse und Studieneinschr\u00e4nkungen bei und unterscheiden ver\u00f6ffentlichte Interventionen von Katalogmaterialien. F\u00fcr die Strukturierung kann AI-unterst\u00fctztes Zeichnen verwendet werden; Quellenverkn\u00fcpfungen und Beweisgrenzen bleiben sichtbar. Bei dieser Arbeit handelt es sich nicht um eine unabh\u00e4ngige Begutachtung oder medizinische Beratung.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/de\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/comments?post=450"}],"version-history":[{"count":3,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/450\/revisions"}],"predecessor-version":[{"id":530,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/450\/revisions\/530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/620"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/categories?post=450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/tags?post=450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}